These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
553 related articles for article (PubMed ID: 33947460)
1. Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease. Aichholzer F; Klafki HW; Ogorek I; Vogelgsang J; Wiltfang J; Scherbaum N; Weggen S; Wirths O Alzheimers Res Ther; 2021 May; 13(1):94. PubMed ID: 33947460 [TBL] [Abstract][Full Text] [Related]
2. Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. Hüttenrauch M; Ogorek I; Klafki H; Otto M; Stadelmann C; Weggen S; Wiltfang J; Wirths O Acta Neuropathol Commun; 2018 Oct; 6(1):108. PubMed ID: 30340518 [TBL] [Abstract][Full Text] [Related]
3. Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer's Disease. Doroszkiewicz J; Kulczyńska-Przybik A; Dulewicz M; Borawska R; Zajkowska M; Słowik A; Mroczko B J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510803 [TBL] [Abstract][Full Text] [Related]
4. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
5. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824 [TBL] [Abstract][Full Text] [Related]
6. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249 [TBL] [Abstract][Full Text] [Related]
7. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
13. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW; Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191 [TBL] [Abstract][Full Text] [Related]
14. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL; Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM; Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642 [TBL] [Abstract][Full Text] [Related]
16. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476 [TBL] [Abstract][Full Text] [Related]
17. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
18. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging. Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627 [TBL] [Abstract][Full Text] [Related]
20. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]